title: Differences in drug-eluting stents used in coronary artery disease.
abstract: The introduction of drug-eluting stents (DES) has improved the efficacy of percutaneous coronary intervention by addressing the issue of neointimal proliferation, a pathology contributing to restenosis. First-generation stents eluting sirolimus or paclitaxel were joined by second-generation stents, such as the everolimus- and the zotarolimus-eluting stents, promising increased safety and efficacy. As a result, there is a plethora of drug-eluting stents available, with differences in the stent platform, the polymer coating and the eluted drug, which translate into differences in biological markers of efficacy, such as late loss. However, it remains controversial whether these discrepancies have an impact on clinical markers of safety and efficacy, or if the improved efficacy of DES is a class effect. This article reviews the differences between DES by looking into the biological differences and into trials and registries of DES.
authors.affiliation: First Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece.
authors.forename: Andreas
authors.initials: A
authors.lastname: Synetos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Toutouzas
authors.forename: Antonis
authors.initials: A
authors.lastname: Karanasos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Stathogiannis
authors.forename: Georgia
authors.initials: G
authors.lastname: Triantafyllou
authors.forename: Eleutherios
authors.initials: E
authors.lastname: Tsiamis
authors.forename: Stamatios
authors.initials: S
authors.lastname: Lerakis
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy*; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D000068338:Everolimus; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus